Publication

Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains [preprint]

Wang, Shixia
Chan, Kun-Wei
Wei, Danlan
Ma, Xiuwen
Liu, Shuying
Hu, Guangnan
Park, Saeyoung
Pan, Ruimin
Gu, Ying
Nazzari, Alexandra F
... show 10 more
Embargo Expiration Date
Abstract

The vaccine elicitation of HIV-neutralizing antibodies with tier-2-neutralization breadth has been a challenge. Here, we report the isolation and characteristics of a CD4-binding site specific monoclonal antibody, HmAb64, from a human volunteer immunized with a polyvalent gp120 DNA prime-protein boost vaccine. HmAb64 derived from heavy chain variable germline gene IGHV1-18, light chain germline gene IGKV1-39, and had a 3 heavy chain complementarity determining region (CDR H3) of 15 amino acids. On a cross-clade panel of 208 HIV-1 pseudo-virus strains, HmAb64 neutralized 21 (10%), including tier-2 neutralization resistant strains from clades B, BC, C, and G. The cryo-EM structure of the antigen-binding fragment of HmAb64 bound to a conformation between prefusion closed and occluded open forms of envelope trimer, using both heavy and light CDR3s to recognize the CD4-binding loop, a critical component of the CD4-binding site. A gp120 subunit-based vaccine can thus elicit an antibody capable of tier 2-HIV neutralization.

Source

Wang S, Chan KW, Wei D, Ma X, Liu S, Hu G, Park S, Pan R, Gu Y, Nazzari AF, Olia AS, Xu K, Lin BC, Louder MK, Doria-Rose NA, Montefiori D, Seaman MS, Zhou T, Kwong PD, Arthos J, Kong XP, Lu S. Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains. Res Sq [Preprint]. 2023 Oct 20:rs.3.rs-3360161. doi: 10.21203/rs.3.rs-3360161/v1. Update in: Nat Commun. 2024 May 21;15(1):4301. doi: 10.1038/s41467-024-48514-8. PMID: 37886518; PMCID: PMC10602183.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.21203/rs.3.rs-3360161/v1
PubMed ID
37886518
Other Identifiers
Notes

This article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.

Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
The copyright holder for this preprint is the author/funder, who has granted Research Square a license to display the preprint in perpetuity. It is made available under a Creative Commons Attribution 4.0 International License.